Lynx Therapeutics
Executive Summary
AML antisense therapeutic approved for "emergency use" in just one patient, not 15 ("The Pink Sheet" July 13, T&G-11). Lynx and the University of Nebraska Medical Center are pursuing an IND for treating up to 15 patients.